MethylGene, Otsuka Collaborate To Develop Kinase Inhibitors For Ocular Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth potential $55 million expands MethylGene’s therapeutic research, development into ocular diseases.